143 related articles for article (PubMed ID: 21049307)
21. Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy.
Avoranta ST; Korkeila EA; Minn HR; Syrjänen KJ; Pyrhönen SO; Sundström JT
Acta Oncol; 2011 Nov; 50(8):1158-66. PubMed ID: 22023115
[TBL] [Abstract][Full Text] [Related]
22. Rectal cancer adjuvant chemotherapy: when is more useful?
Pasetto LM; Basso U; Sinigaglia G; Pucciarelli S; Friso ML; Rugge M; Toppan P; Agostini M; Monfardini S
Anticancer Res; 2008; 28(3B):1805-12. PubMed ID: 18630464
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C
Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847
[TBL] [Abstract][Full Text] [Related]
24. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study.
Kuo YH; Lai CH; Huang CY; Chen CJ; Huang YC; Huang WS; Chin CC
BMC Cancer; 2019 Aug; 19(1):815. PubMed ID: 31419963
[TBL] [Abstract][Full Text] [Related]
25. Still proliferating CD44
Klose J; Schmitt A; Pernthaler J; Warschkow R; Büchler MW; Schneider M; Lasitschka F; Tarantino I
Eur J Surg Oncol; 2021 Aug; 47(8):2078-2086. PubMed ID: 33814238
[TBL] [Abstract][Full Text] [Related]
26. [Correlation of VEGF and Ki67 expression with sensitivity to neoadjuvant chemoradiation in rectal adenocarcinoma].
Jiang SM; Wang RB; Yu JM; Zhu KL; Mu DB; Xu ZF
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):602-5. PubMed ID: 19102938
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Abdul-Jalil KI; Sheehan KM; Kehoe J; Cummins R; O'Grady A; McNamara DA; Deasy J; Breathnach O; Grogan L; O'Neill BD; Faul C; Parker I; Kay EW; Hennessy BT; Gillen P
Colorectal Dis; 2014 Jan; 16(1):O16-25. PubMed ID: 24119076
[TBL] [Abstract][Full Text] [Related]
28. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
Sastre J; Custodio A; Sanchez JC; Ortega L; Rodriguez L; Puente J; Corona J; Alfonso R; de las Heras M; Dıaz-Rubio E
Anticancer Drugs; 2011 Feb; 22(2):185-90. PubMed ID: 21218606
[TBL] [Abstract][Full Text] [Related]
29. Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.
Imaizumi K; Suzuki T; Kojima M; Shimomura M; Sakuyama N; Tsukada Y; Sasaki T; Nishizawa Y; Taketomi A; Ito M; Nakatsura T
Cancer Sci; 2020 Jan; 111(1):23-35. PubMed ID: 31660687
[TBL] [Abstract][Full Text] [Related]
30. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Habr-Gama A; Perez RO; Nadalin W; Sabbaga J; Ribeiro U; Silva e Sousa AH; Campos FG; Kiss DR; Gama-Rodrigues J
Ann Surg; 2004 Oct; 240(4):711-7; discussion 717-8. PubMed ID: 15383798
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
32. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Edden Y; Wexner SD; Berho M
Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Allegra CJ; Yothers G; O'Connell MJ; Beart RW; Wozniak TF; Pitot HC; Shields AF; Landry JC; Ryan DP; Arora A; Evans LS; Bahary N; Soori G; Eakle JF; Robertson JM; Moore DF; Mullane MR; Marchello BT; Ward PJ; Sharif S; Roh MS; Wolmark N
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26374429
[TBL] [Abstract][Full Text] [Related]
34. Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin.
Martin LK; Bekaii-Saab T
J Natl Compr Canc Netw; 2013 Mar; 11(3):298-307; quiz 307. PubMed ID: 23486456
[TBL] [Abstract][Full Text] [Related]
35. Improving chemoradiotherapy in rectal cancer.
Glynne-Jones R; Debus J
Oncologist; 2001; 6 Suppl 4():29-34. PubMed ID: 11585972
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174
[TBL] [Abstract][Full Text] [Related]
37. A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
Myerson RJ; Valentini V; Birnbaum EH; Cellini N; Coco C; Fleshman JW; Gambacorta MA; Genovesi D; Kodner IJ; Picus J; Ratkin GA; Read TE
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1299-308. PubMed ID: 11483342
[TBL] [Abstract][Full Text] [Related]
38. Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.
Yang L; Sun Y; Huang XE; Yu DS; Zhou JN; Zhou X; Li DZ; Guan X
Asian Pac J Cancer Prev; 2015; 16(4):1545-51. PubMed ID: 25743829
[TBL] [Abstract][Full Text] [Related]
39. Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy.
Perez RO; Habr-Gama A; Nishida Arazawa ST; Rawet V; Coelho Siqueira SA; Kiss DR; Gama-Rodrigues JJ
Int J Colorectal Dis; 2005 Sep; 20(5):434-9. PubMed ID: 15759124
[TBL] [Abstract][Full Text] [Related]
40. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Habr-Gama A; Perez RO; Proscurshim I; Campos FG; Nadalin W; Kiss D; Gama-Rodrigues J
J Gastrointest Surg; 2006 Dec; 10(10):1319-28; discussion 1328-9. PubMed ID: 17175450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
